ai3Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ai3Bio - overview
Location
-, -, US
Primary Industry
Biotechnology
About
based in Massachusetts, US, and co-founded in 2025, ai3Bio is a biotechnology company that research and develops immunology-based therapies for autoimmune diseases through its platforms use lipid nanoparticle (LNP)/mRNA and antibody technologies to identify and eliminate disease-causing T cells directly in vivo, aiming to restore immune balance at the source of disease.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT
Website
www.ai3.bio
Verticals
Artificial Intelligence, HealthTech, Nanotechnology, Research (Non-Medical)
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.